Objective: Clear cell renal cell carcinoma (ccRCC) is a subtype of kidney cancer defined by robust lipid accumulation, which prior studies have indicated plays an important role in tumor progression. We hypothesized that the peroxisome proliferator-activated receptor gamma (PPARg), detected in both ccRCC tumors and cell lines, promotes lipid storage in ccRCC and contributes to tumorigenesis in this setting. PPARg transcriptionally regulates a number of genes involved in lipid and glucose metabolism in adipocytes, yet its role in ccRCC has not been described. The objective of this study was to elucidate endogenous PPARg function in ccRCC cells. Methods and results: Using chromatin immunoprecipitation followed by deep sequencing (ChIP-seq), we found that PPARg and its heterodimer RXR occupy the canonical DR1 PPAR binding motif at approximately 1000 locations throughout the genome that can be subdivided into adiposeshared and ccRCC-specific sites. CRISPR-Cas9 mediated, loss-of-function studies determined that PPARg is dispensable for viability, proliferation, and migration of ccRCC cells in vitro and in vivo. Also, surprisingly, PPARg deletion had little effect on the robust lipid accumulation that typifies the "clear cell" phenotype of kidney cancer. Conclusion: Our results suggest that PPARg plays neither a tumor suppressive nor oncogenic role in advanced ccRCC, and thus single-agent therapeutics targeting PPARg are unlikely to be effective for the treatment of this disease. The unique cistrome of PPARg in ccRCC cells demonstrates the importance of cell type in determining the functions of PPARg.
INTRODUCTION
Kidney cancer is the 8th most prevalent form of cancer diagnosed each year in the United States, with approximately 64,000 new diagnoses and 14,400 deaths annually [1] . While localized disease can be treated by surgical resection, 30% of patients initially present in the clinic with metastatic disease, which carries a poor prognosis due to limited efficacy of current standard-of-care therapies [2] . As such, a significant clinical need remains for therapeutics targeting unique genetic and metabolic vulnerabilities within this tumor type. Clear cell renal cell carcinoma (ccRCC), the most common subtype of kidney cancer, is defined by constitutive hypoxia-inducible factor signaling as well as widespread changes in cellular metabolism of glucose, amino acids, and lipids [3] . Phenotypically, ccRCC is characterized by robust intracellular lipid and glycogen accumulation, resulting in "cleared" cytoplasm when prepared for common histologic analyses. Rather than simply reflecting a byproduct of increased anabolic metabolism, recent studies suggest that maintaining the integrity of neutral lipid droplets as well as abundant lipid uptake is critical to maintain ccRCC cell viability [4] , particularly when oxygen is limiting in the tumor microenvironment [5] . However, factors imparting a lipogenic quality to ccRCC tumors remain to be fully elucidated.
The peroxisome proliferator-activated receptor gamma (PPARg) along with its heterodimeric DNA-binding partner retinoid X receptor (RXR) promote the transcription of genes broadly important for lipid, glucose, and hormone metabolism, most notably in the context of adipose tissue [6] . PPARg, the master regulator of adipogenesis, is both necessary and sufficient for this process in vitro and in vivo [7] [8] . Additionally, in non-adipose contexts including ischemic, diseased cardiomyocytes [9] and macrophages [10] , PPARg contributes to the regulation of genes involved in lipid metabolism. In a mouse model of high fat diet (HFD)-induced hepatosteatosis, PPARg protein expression is elevated in the livers of mice fed HFD relative to controls [11] , although the absolute level remains far below those observed in adipose tissues. Interestingly, conditional deletion of Pparg within hepatocytes abrogated liver steatosis, suggesting a link between PPARg and lipid uptake, synthesis, and/or storage in this model. Previous reports indicate that PPARg is functionally expressed [12] in ccRCC and that increased PPARg abundance correlates with reduced patient survival [13] , suggesting a possible oncogenic function. In vitro studies investigating the role of PPARg in ccRCC and other cancers have largely employed natural and synthetic activating ligands including the insulin-sensitizing thiazolidinediones, yet many used super-physiologic concentrations, which can cause off-target effects and confound interpretation of results [14, 15] . In this study, our goal was to investigate endogenous PPARg function through ChIP-seq and a number of in vitro and in vivo assays of tumor progression using lossof-function models in established ccRCC cell lines. [17] . Mature antisense human PPARG shRNA #3 sequence (clone ID: TRCN0000001673) along with scrambled (SCR) control were cloned into a doxycycline-inducible pLKO lentiviral plasmid (AddGene, cat. 21915, [18] ). Lentivirus was prepared by co-transfection of 293T cells with shRNA or CRISPR plasmid of interest along with packaging plasmids pVSVg (AddGene, cat. 8454), psPAX2 (AddGene, cat. 12260) and Fugene6 transfection reagent (Promega). Lentivirus-containing media was collected from plates at 24 and 48 h post-transfection, filtered using a 0.45 mm filter, and stored at À80 C. For viral transduction, cells were incubated with lentivirus-containing medium and 8 mg/mL polybrene for 24 h. Cells were allowed to recover for another 24 h before selection with puromycin. All experiments were performed with cells that survived puromycin selection and displayed knockdown/knockout of PPARG as assayed by western blot.
MATERIALS AND METHODS

2
Quantitative real-time PCR (qRT-PCR)
Total RNA was isolated using TRIzol reagent (ThermoFisher Scientific, cat. 15596026) and RNeasy mini kit (Qiagen, cat. 74104). Reverse transcription was performed using High-Capacity RNA-to-cDNA (Applied Biosystems, cat. 4387406). qRT-PCR was performed using ViiA7 RealTime PCR system (Applied Biosystems) with TaqMan master mix (Life Technologies). TaqMan probes were used to quantitate expression of PPARG (cat. Hs01115513_m1), FABP4 (cat. Hs01086177_m1), CD36 (cat. Hs01567185_m1) SLC38A4 (Hs00394339_m1) and normalized to housekeeping genes HPRT1 (cat. Hs02800695_m1) and TBP (Hs00427620_m1).
Western blot
Cells were washed with PBS prior to lysis in whole cell elution buffer (150 mM NaCl, 10 mM Tris pH 7.6, 0.1% SDS, and 5 mM EDTA) for immunoprecipitation (IP). Briefly, confluent 10 cm dishes of cells were prepared by crosslinking with 1% formaldehyde for 15 min at room temperature and quenched with 125 mM glycine for 5 min at room temperature. Cells were harvested by scraping and pellets were resuspended in 200 ml SDS lysis buffer (50 mM HEPES/NaOH pH 7.5, 1% SDS, 10 mM EDTA, 1 mM PMSF, and Roche ULTRA protease inhibitor cocktail (cat. 05892791001)) on ice for 10 min. Sonication was performed using Bioruptor Pico (Diagenode, cat. B01060010) on high setting for 30 s, followed by centrifugation of lysates to remove cellular debris. 100 ml of sheared chromatin from each tube was then diluted 10X, with 5% saved as Input DNA and the rest prepared for either PPARg or RXR IP. PPARg WT, PPARg KD, RXR, and Input libraries were prepared in duplicate from two independent biological replicates. For ChIP-seq, sequencing data was mapped to the human genome (GRCh38) using STAR [19] with parameters appropriate for ungapped alignments. Peaks were called for each sample with input samples as background by HOMER [20] . HOMER was also used for differential peak calling (PPARg WT vs. KD and RXR WT vs. KD) and to annotate peaks to proximal genes as described in Ensembl v85 (http://www.ensembl. org/index.html). For bioinformatics analyses displayed in Figure 2C , F, 1031 "high-confidence sites" were defined by the following criteria: peak score !10 (!1 read per million), fold change (PPARg WT vs. KD) ! 2, RXR peak called with strict overlap. Motif enrichment analysis was performed on this filtered peak list (1031 peaks) using HOMER against the standard list of known motifs; de novo motif discovery included consideration of lengths 8, 10, 12, 15,18 bp.
2.6. Annexin V-PI apoptosis assay 30,000 cells of each cell line were plated in triplicate on 6-well plates. Four days later, cells were prepared using the FITCeAnnexin V, PI Kit (BD Biosciences, cat. 556547) according to the manufacturer's instructions. Flow cytometry was performed using the BD Accuri C6 instrument, with viable cells represented as the double-negative population.
2.7. 2D and 3D proliferation assays For 2D proliferation assays, 30,000 cells of each cell line were plated in triplicate on 6-well plates. The following day (represented as Day 0), cells were trypsinized and counted using the Countess Automated Cell Counter (Invitrogen, cat. C10281), as per the manufacturer's instructions with Trypan blue. Cells were then counted again at the indicated timepoints. For 3D proliferation assays, 3,000 cells of each cell line were plated in 24 wells of a Corning Costar 96-well Ultra-low attachment round bottom plate (SigmaeAldrich, cat. CLS7007) [21] . Cells were mixed with Matrigel (BD Biosciences, cat. 356234) at a final concentration of 2.5%, and plates were centrifuged at 1800 rpm for 10 min to form spheroids. The following day (represented as Day 0), spheroids were imaged using the Invitrogen EVOS FL Auto Cell Imaging System and were imaged again, at the indicated timepoints, over the course of two weeks. Spheroid volume was calculated using a previously published ImageJ macro [22] . De novo motif analysis of PPARg and RXR binding sites. For bioinformatics analyses displayed in C-F, 1031 "high-confidence sites" were defined by the following criteria: peak score !10 (!1 read per million), fold change (WT vs. KD) !2, RXR peak called with strict overlap. D. Frequency of PPARg-RXR heterodimer occupancy at various genomic locations, defined by HOMER annotate peaks. E. Gene ontology of PPARg and RXR binding sites, annotated to nearest gene. 367/1031 genes (36%) were directly shared with human adipose. Data were compared to published PPARg ChIP-seq from an adipocyte cell line [31] . Numbers in parenthesis indicate number of genes per category. F. Gene ontology of PPARg and RXR binding sites, annotated to nearest gene. 664/1031 genes (64%) were unique to ccRCC. Data were compared to published PPARg ChIP-seq from an adipocyte cell line [31] . Numbers in parenthesis indicate number of genes per category.
, where L was the longer measurement and W was the shorter measurement. At Day 75 postinjection, mice were sacrificed by CO 2 inhalation, and tumors were dissected for further analyses.
Immunohistochemistry
Xenograft tumors were dehydrated, embedded in paraffin, and sectioned for staining. Immunohistochemistry was performed as previously described [4] 2.12. Triglyceride measurement Xenograft tumors were homogenized in complete lysis buffer (50 mM Tris pH 7.4, 140 mM NaCl, 0.1% Triton X-100, 1 mM PMSF) containing Roche ULTRA protease inhibitor cocktail (cat. 05892791001) using a Tissue-Tearor (BioSpec Products, cat. 985370). Triglyceride content was measured using the LiquiColor Triglycerides kit (Stanbio Laboratory, cat. 2100) according to the manufacturer's instructions, and data were normalized to weight of each sample.
Statistics
Statistical analyses were performed using GraphPad Prism version 7 software, using unpaired t-test with Welch's correction. Data are presented as mean AE SEM of at least three independent experiments. Statistical significance was defined as *** (p < 0.001), ** (p < 0.01), * (p < 0.05), n.s. ¼ not significant.
RESULTS
PPARg expression in ccRCC patient samples and cell lines
A 43 megabase region of chromosome 3p harbors bona fide and putative tumor suppressor genes in ccRCC [23] including von HippelLindau (VHL), the most commonly mutated gene in ccRCC and initiating tumorigenic event [24] . Unlike tumor suppressor genes located in this region, such as VHL, SETD2, PBRM1, and BAP1, PPARG is free from mutations which could render the protein non-functional or functional as a dominant-negative factor and retains wildtype sequence in 96% of ccRCC tumors ( Figure 1A) . PPARG mRNA expression is elevated in early-stage ccRCC relative to matched healthy kidney tissue ( Figure 1B) [25, 26] . The Cancer Genome Atlas (TCGA) RNA-seq data stratified according to tumor stage confirmed a significant increase in PPARG transcripts in stage I and II patients, with non-significant changes in stages III and IV relative to normal kidney tissue ( Figure 1C ). To verify PPARG mRNA and protein expression in ccRCC, we examined matched tumor/normal pairs by RT-qPCR and Western blot. PPARG mRNA ( Figure 1D ) and protein ( Figure 1E ) abundances were variable between tumor/normal samples, yet a subset of samples displayed elevated PPARg expression relative to adjacent healthy kidney tissue. PPARg expression in the kidney is highest in medullary collecting ducts [27, 28] and is not expressed significantly in renal proximal tubule epithelial cells (RPTEC), a proposed cell-of-origin for ccRCC [29, 30] . This may explain the heterogeneity observed across the kidney lysates sampled. We further examined PPARg expression in a panel of ccRCC cell lines relative to immortalized (HK2) and purified primary (RPTEC) cells ( Figure 1F , G) and found elevated mRNA and protein abundance in ccRCC relative to control in 4 out of 6 lines tested.
Genome-wide analysis of PPARg-RXR binding in ccRCC
To understand the functional role of PPARg in kidney cancer, we sought to characterize the PPARg-RXR cistrome in the context of ccRCC and determine the relatedness of genomic occupancy to that found in adipocytes. ChIP-qPCR interrogating a number of adipocyte sites [31] in the UMRC2 cell line revealed coordinated occupancy for PPARg and its heterodimeric binding partner RXR at PDK4 and PLIN1 (Figure 2A ). To examine occupancy across the entire genome, we performed chromatin immunoprecipitation followed by deep sequencing (ChIP-seq) for PPARg and RXR. We identified 1031 binding sites based on the following criteria: peak score greater than or equal to 10, wildtype vs. knockdown fold change greater than or equal to 2 (validation of PPARg protein knockdown in Supplementary Fig. 1A) , and RXR peak called with strict overlap (Figure 2B , Supplementary Table 1) . We validated PPARg binding at eight of the top sites called in our data set based on peak score using control and PPARG KO cells (Supplementary Figs. 2AeC) . Additionally, we addressed the functionality of PPARg binding in ccRCC cells through an shRNA-resistant cDNA rescue experiment. Ectopic expression of PPARg increased the expression of SLC38A4, a gene with two PPARg-RXR binding sites within 10 kb of the transcriptional start site ( Supplementary Figs. 2D  and 2E ). When cells were treated with shRNA targeting PPARG, SLC38A4 expression was diminished, but not when cells also contained the resistant cDNA ( Supplementary Fig. 2F ). These data suggest that SLC38A4 is a direct transcriptional target of PPARg in ccRCC and provide evidence that endogenous PPARg activity regulates gene expression in our cell culture models. Through de novo motif analysis, we found that the canonical nuclear receptor direct repeat 1 (DR1) motif is most highly enriched under PPARg-RXR bound DNA in ccRCC, present at 60.3% of sites ( Figure 2C ). Other transcription factor motifs represented include RAR-related orphan receptor alpha (RORA) at 17.3% of sites and the hepatocyte nuclear factors alpha (HNF1A, 16.3% of sites) and gamma (HNF4G, 5.7% of sites). Interestingly, the C/EBP motif, which is found at 91% of PPARg-binding regions in adipocytes [32] , is only found at 4.6% of PPARg-RXR-bound regions in ccRCC. Consistent with previously published ChIP-seq data sets in tissues including adipocytes and macrophages [33, 34] , PPARg-RXR is bound most frequently at intergenic (37.2%) and intronic (47.1%) regions of the genome in ccRCC, rather than at promoter-transcriptional start sites (10.4%) ( Figure 2D ). We then annotated peaks to the nearest gene and performed gene ontology analysis to determine putative PPARg-regulated pathways in ccRCC. Annotation of "adipose-shared" genes include "metabolism of lipids and lipoproteins", "organic acid metabolic process", and "lipid localization" (Figure 2E ), whereas "ccRCCspecific" genes belonged to cellular processes broadly important in cancer cell biology, including signal transduction and regulation of cell shape and size ( Figure 2F ).
PPARg is dispensable for ccRCC viability and proliferation in vitro
As PPARg was shown to bind near genes associated with regulation of protein serine/threonine kinase activity and G2/M transition of mitotic cell cycle in ccRCC ( Figure 2F ), we hypothesized that its loss would affect cell growth over time. Upon confirming effective knockout of PPARg using CRISPR-Cas9 ( Figure 3A, Supplementary Fig. 1B) , we subjected UMRC2 and A498 ccRCC cell lines to a variety of in vitro assays to determine the functional consequence of PPARg loss. PPARG KO did not affect the viability (Figure 3B, C) or proliferation rate ( Figure 3D , E) of either cell line when cells were grown in replete conditions (21% O 2 , 25 mM glucose and 10% FBS). Since oxygen and nutrient limitation can profoundly influence cancer cell growth, we embedded control and PPARG KO cells in Matrigel and allowed tumor spheroids to proliferate over the course of two weeks. PPARG KO did not affect spheroid volume during the assay (Figure 3FeH) . Additional "ccRCC-specific" PPARg bound genes included those involved in "regulation of cell shape" and "regulation of locomotion", which we hypothesized could affect migratory capacity. We plated UMRC2 and A498 cells to confluency and performed an in vitro scratch assay to measure migration over the course of 16 h, a timepoint chosen based on the nearly complete recovery of the wound prior to the doubling time. We found no significant difference in the percentage of wound healing that occurred between control and PPARG KO cells ( Supplementary Figs. 3A and 3B ). We also found that PPARg depletion only modestly affected anchorage-independent growth of UMRC2 and A498 ccRCC cells ( Supplementary Figs. 3C and 3D ).
PPARg is dispensable for ccRCC xenograft tumor growth in vivo
To assess the function of PPARg in ccRCC tumor growth in vivo, we implanted UMRC2 control and PPARG KO cells subcutaneously into opposing flanks of NIH-III nude mice. Analysis of tumor volume ( Figure 4A ) over the course of the experiment and tumor weights at day 75 post-injection ( Figure 4B ) revealed no significant difference in the growth of PPARG KO tumors relative to control. Additionally, control and PPARG KO tumors were sectioned and immunohistochemistry was performed for markers of proliferation (Ki67) and apoptosis (cleaved caspase-3), as well as to confirm PPARg loss over the duration of the assay ( Figure 4C ). Quantitation of these markers revealed no significant difference between control and PPARG KO tumors, suggesting that PPARg is dispensable for ccRCC cell growth in vivo (Figure 4D, E) .
3.5. Lipid storage and triglyceride synthesis occur independently of PPARg in ccRCC As PPARg is responsible for promoting lipid uptake and storage in adipocytes and is bound near lipid metabolism related genes in our model ( Figure 2E ), we hypothesized that its loss in ccRCC would reduce neutral lipid content. Surprisingly, we found that loss of PPARg did not affect lipid accumulation in either ccRCC cell line tested in vitro by Oil Red O ( Figure 5A ) or BODIPY 493/503 ( Figure 5B ) staining. In agreement with this, expression of a number of proteins involved in de novo lipogenesis that are reduced following hepatocyte-specific deletion of PPARg [11] , including sterol regulatory element-binding protein 1 (SREBP1), fatty acid synthase (FASN), and stearoyl-CoA desaturase 1 (SCD), did not change substantially following PPARg loss in our models ( Figure 5C ). Additionally, we measured triglyceride levels in control and PPARG KO xenograft tumors to determine whether exposure to oxygen and nutrient depletion in vivo would affect the ability of the cells to store triglyceride. Consistent with our in vitro results, we found no significant difference in triglyceride content between control and PPARG KO tumors ( Figure 5D ). These data indicate that PPARg is dispensable for the "clear cell" phenotype of renal cancer with regard to triglyceride synthesis and storage.
DISCUSSION
"Druggability" of nuclear receptors via small molecule agonists or antagonists make them appealing therapeutic targets to treat diseases like diabetes and cancer. Across various tumor types, studies have revealed both oncogenic and tumor suppressive roles for PPARg [35] . Heterozygous deletion of PPARg in mice has demonstrated that it primarily acts as a tumor suppressor in chemically-induced models of colon [36] , breast, ovarian and skin cancers [37] , whereas newly uncovered oncogenic functions for PPARg have been reported in bladder cancer using in vitro cell culture models [38, 39] . We hypothesized that PPARg would promote ccRCC tumorigenesis due to the fact that its lipid-laden phenotype is tightly linked to cell viability and proliferation. Our lab previously reported that suppression of the lipid droplet coat protein perilipin 2 in ccRCC reduces neutral lipid accumulation, engaging the endoplasmic reticulum stress response and causing tumor regression [4] . Additionally, cells defined by constitutive mTORC1 signaling such as ccRCC [16, 40] require import of exogenous unsaturated fatty acids during hypoxia to maintain membrane homeostasis and prevent cell death [5, 41] . However, our current understanding of the molecular mediators of lipid uptake and storage in ccRCC is limited. In this study, we performed loss-of-function experiments to elucidate PPARg 0 s role in ccRCC in established cell lines both in vitro and in vivo. PPARg deletion in two ccRCC cell lines affected neither viability, proliferation, migratory capacity in vitro, nor tumor growth in a subcutaneous xenograft model. Surprisingly, we also show that PPARg is dispensable for lipid storage and maintenance of total triglyceride levels in ccRCC cells grown both in vitro and in vivo. While our data collectively suggest that PPARg is not required for ccRCC progression, we cannot exclude a potential role for this nuclear receptor in tumor initiation. The stage-specific upregulation of PPARG transcripts in stage I and II kidney tumors (Figure 1BeC ) is consistent with PPARg protein expression patterns in human prostate cancer [42] . Functionally, this may reflect a role for PPARg in epithelial-tomesenchymal transition of renal epithelium to ccRCC, although this remains to be explored. PPARG expression may also be inversely related to the differentiation status of tumors, as previously reported in liposarcoma [43, 44] . One factor that may influence PPARg 0 s function in regulating ccRCC gene expression is cooperative transcription factor binding. For example, CCAAT-enhancer-binding proteins (C/EBPs) have been shown to be required for robust PPARg target gene expression in adipocytes [32] , yet the C/EBP motif only appeared under w5% of the binding sites called in ccRCC ( Figure 2C ). Lack of PPARg/C/EBP cooperativity may underlie the lack of "classic" PPARg target gene expression including CD36, FABP4, and other genes broadly important in lipid and glucose metabolism (Supplementary Fig. 1C ) and demonstrate distinct PPARg action in ccRCC vs. adipose tissue. Additionally, de novo motif analysis revealed that the retinoic acid receptor-related orphan receptor alpha (RORa) motif is the second most commonly enriched motif under PPARg-RXR-bound DNA in ccRCC ( Figure 2C) . A recent report demonstrated that RORa reduces PPARg transcriptional activity via the recruitment of histone deacetylase 3 to PPARg target gene promoters in the livers of mice fed HFD [45] . PPARg-RORa co-localization in ccRCC and negative regulation of lipid metabolism-related genes would be consistent with the phenotypes observed in our experiments, as PPARg depletion did not reduce triglyceride content or significantly alter expression of de novo lipogenesis enzymes ( Figure 5 ). H. Representative images of UMRC2 and A498 control and PPARG KO tumor spheroids at indicated timepoints. Scale bar ¼ 100 mm.
We considered that compensatory up-regulation of other PPAR family members may underlie the lack of phenotypes observed in our experiments; however, we determined that PPARG KO cells do not increase expression of PPARA or PPARD (Supplementary Fig. 1D ). Indeed, expression of PPARA, PPARGC1A, and additional genes involved in beta-oxidation of lipids are highly suppressed in ccRCC relative to healthy renal tubule epithelium [46] . Ectopic expression of such factors in ccRCC reduces tumor growth [47] , further illustrating the importance of reprogramming lipid metabolism from an oxidative to anabolic state in this tumor type. In conclusion, our investigation of PPARg in ccRCC led to a novel PPARg-RXR cistrome, which shares both similarities and differences with published cistromes in tissues such as adipocytes and macrophages. Of note, our dataset will be beneficial to researchers studying cell type-specific functions of PPARg in cancer as well as the role of other subfamily 1 nuclear receptors that heterodimerize with RXR in ccRCC. Finally, while PPARg is expressed in ccRCC tumors, it does not appear to be necessary for tumor maintenance based on our assays. 
